8-K: Aptevo Therapeutics Secures $25 Million Equity Purchase Agreement to Bolster Capital

Aptevo Therapeutics Inc. has entered into a Standby Equity Purchase Agreement with Yorkville for up to $25 million in common stock, providing flexible access to capital over 36 months.

Summary

• Aptevo Therapeutics Inc. (the "Company") entered into a Standby Equity Purchase Agreement (the "Purchase Agreement") with YA II PN, LTD. (Yorkville) on June 16, 2025.
• The agreement grants the Company the right, but not the obligation, to issue and sell up to $25.0 million (the "Commitment Amount") of its common stock to Yorkville over a 36-month period.
• Shares will be purchased at a price equal to 96% of the lowest daily Volume Weighted Average Price (VWAP) during a three-consecutive-trading-day period.
• The Company retains the option to specify a minimum acceptable price per share for each advance.
• As consideration for Yorkville's commitment, Aptevo paid a structuring fee of $25,000 and agreed to a commitment fee of 2.00% of the Commitment Amount ($500,000), payable in five equal quarterly installments.
• Issuance of shares is subject to Nasdaq rules, including an "Exchange Cap" of 19.99% (151,755 shares) of the common stock outstanding as of the effective date, unless stockholder approval is obtained or the average price of all applicable sales equals or exceeds $3.66 per share.
• Yorkville's obligation to purchase shares is also limited by an "Ownership Limitation," preventing their beneficial ownership from exceeding 9.99% of the Company's then outstanding voting power or common shares.
• The agreement requires a registration statement to be filed with the SEC to register the advance shares.

Sentiment

Score: 6

Explanation: The agreement provides crucial access to capital for a development-stage biotech company, which is a positive for its operational continuity and strategic initiatives. However, the potential for significant shareholder dilution and the associated fees temper the overall positive sentiment, making it a necessary but costly financing mechanism.

Positives

• Provides flexible access to up to $25.0 million in capital over a 36-month period, which is crucial for a development-stage biotechnology company.
• The Company has the right, but not the obligation, to draw funds, offering strategic financial flexibility to manage its cash needs.
• The ability to specify a minimum acceptable price per share for each advance can help protect against significant dilution if the stock price falls too low.
• The capital infusion can support ongoing research and development, clinical trials, and general corporate purposes, potentially advancing the Company's pipeline.

Negatives

• Potential for significant shareholder dilution if the Company utilizes the full $25.0 million commitment, especially if shares are issued at lower market prices.
• The purchase price is at a 4% discount (96% of VWAP), which represents a cost to existing shareholders.
• The Company incurs a $25,000 structuring fee and a 2.00% commitment fee ($500,000) on the total commitment, adding to the cost of capital.
• The "Exchange Cap" of 19.99% (151,755 shares) or an average price threshold of $3.66 per share may limit the Company's ability to access the full $25 million without further shareholder approval.
• Yorkville's agreement to use commercially reasonable efforts to sell most of the Advance Shares within a reasonable time could create selling pressure on the stock.

Risks

• **Dilution Risk**: The issuance of new common shares under the agreement will dilute the ownership interest of existing shareholders.
• **Price Volatility Risk**: The purchase price is tied to the volume-weighted average price (VWAP), meaning the Company will sell shares at market-determined prices, which could be low and exacerbate dilution.
• **Market Conditions Risk**: Yorkville's obligation to purchase shares is subject to certain conditions, and their intent to sell shares within a reasonable time could increase selling pressure on the stock.
• **Regulatory Limitations (Exchange Cap)**: The Company cannot issue shares exceeding 19.99% of outstanding shares (151,755 shares) without shareholder approval or if the average price of sales is below $3.66 per share, potentially limiting access to the full $25 million.
• **Ownership Limitation**: Yorkville is not obligated to purchase shares if it would result in their beneficial ownership exceeding 9.99% of the Company's voting power or common shares.
• **Registration Statement Effectiveness**: Yorkville's obligation to purchase shares is contingent on the effectiveness of a registration statement with the SEC for the advance shares.
• **Material Adverse Event**: The Company's ability to draw funds is subject to no Material Outside Event occurring, which could halt financing.
• **Black Out Periods**: The Company can suspend the use of the registration statement during "Black Out Periods" (e.g., for material non-public information), during which no advances can be made.

Future Outlook

The proceeds from the sale of shares by the Company to Yorkville are intended to be used in the manner set forth in the Prospectus included in any Registration Statement and any Prospectus Supplement thereto. This typically implies funding for general corporate purposes, including research and development, clinical trial advancement, and working capital, which are common needs for biotechnology companies.

Industry Context

Standby Equity Purchase Agreements (SEPAs), also known as equity lines, are a common financing tool for small-cap companies, particularly prevalent in the biotechnology and pharmaceutical sectors. These industries often require substantial capital for lengthy and uncertain research and development cycles and clinical trials, without significant immediate revenue streams. SEPAs provide flexible, 'at-the-market' access to capital, allowing companies to draw funds as needed, often when their stock price is favorable. This type of financing helps companies manage their cash burn and fund operations without the immediate pressure of traditional equity offerings or the fixed obligations of debt, but it carries the inherent risk of dilution.

Comparison to Industry Standards

• The 4% discount (96% of VWAP) at which shares are purchased is within the typical range for SEPA agreements in the biotech industry, which commonly see discounts from 3% to 7%.
• The 19.99% Exchange Cap is a standard provision in such agreements, designed to comply with Nasdaq rules that require shareholder approval for issuances exceeding 20% of outstanding shares.
• The $25 million commitment amount is a moderate size for a company with 759,156 shares outstanding. If fully utilized at the $3.66 threshold price, it would result in the issuance of approximately 6.83 million shares, representing a significant potential dilution of over 900% relative to the current outstanding shares. This level of potential dilution is substantial, even for a development-stage biotech company, and highlights the high capital needs and associated risks in the sector.
• The inclusion of a minimum acceptable price option provides some protection against extreme dilution, a feature often sought by companies entering these agreements.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution of their ownership interest due to the issuance of new common shares, especially if shares are sold at lower prices. The 4% discount on the purchase price also represents a cost. However, access to capital can fund critical operations and potentially increase long-term value if the Company's pipeline progresses successfully.
• **Employees**: The secured capital helps ensure continued operations, funding for research and development projects, and potentially job security and future growth opportunities.
• **Creditors**: Improved liquidity and financial stability resulting from the capital raise could reduce credit risk and enhance the Company's ability to meet its financial obligations.

Next Steps

• The Company will prepare and file a registration statement with the SEC to register the advance shares for resale by Yorkville.
• The Company will file a current report on Form 8-K describing the material terms of the transaction, including the Purchase Agreement as an exhibit.
• The Company will make the first installment of the commitment fee within five days of the agreement's execution, followed by four more quarterly installments.
• The Company may deliver Advance Notices to Yorkville to request purchases of common stock as needed over the 36-month commitment period.
• The Company will use commercially reasonable efforts to maintain the effectiveness of the registration statement during the commitment period.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, Standby Equity Purchase Agreement, SEPA, Yorkville, YA II PN, LTD., capital raise, equity financing, common stock, dilution, Nasdaq, biotech, pharmaceutical, financial agreement, investment, corporate finance